COMMUNIQUÉS West-GlobeNewswire

Momenta Pharmaceuticals Announces Positive Outcome for Contracted Glatopa® (glatiramer acetate injection) Fill/Finish Manufacturer

30/01/2018 - 14:00

-- McPherson, Kansas facility compliance status amended to Voluntary Action Indicated (VAI)-- -- VAI status provides the potential for the near-term FDA approval of Sandoz’s Glatopa 40 mg ANDA-- CAMBRIDGE, Mass., Jan. [...]

CymaBay Announces Pricing of Public Offering of Common Stock

30/01/2018 - 14:00

NEWARK, Calif., Jan. 30, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY ), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high [...]

First Patient Treated in Mapi Pharma’s Phase II Clinical Trial of GA Depot for Primary Progressive Multiple Sclerosis (PPMS)

30/01/2018 - 14:00

Study is being conducted on strength of prior Phase II clinical trial that showed strong efficacy in RRMS patients who switched from Copaxone ® to once-monthly GA Depot NESS ZIONA, Israel, Jan. 30, 2018 (GLOBE NEWSWIRE [...]

Emerald Health Therapeutics and Namaste Technologies Announce Letter of Intent for International Partnership and Supply Agreement

30/01/2018 - 13:30

VICTORIA, British Columbia and VANCOUVER, British Columbia, Jan. 30, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics Inc. (“Emerald”) (TSXV:EMH) (OTCQX:EMHTF) and Namaste Technologies Inc. (“Namaste”) (CSE:N) ( [...]

REPEAT: Cannabis Wheaton Income Corp. Announces Expansion to Uruguay and Securing of Significant CBD-Rich Hemp Production

30/01/2018 - 13:30

VANCOUVER, British Columbia, Jan. 30, 2018 (GLOBE NEWSWIRE) -- Cannabis Wheaton Income Corp. (d/b/a Wheaton Income) (TSX-V: CBW ) (" Wheaton Income " or "Wheaton" or the " Company ") is pleased to announce that it has [...]

AB Biosciences and Shire Enter Into Agreement for Development and Commercialization of AB Biosciences' PRIM Program

30/01/2018 - 13:01

AB Biosciences and Shire Enter Into Agreement for Development and Commercialization of AB Biosciences' PRIM Program for Potential Treatment of Autoimmune Diseases and Other Immune-Mediated Disorders AB Biosciences to [...]

Madrigal Announces Acceptance of MGL-3196 Abstract for a Main Plenary Presentation at The International Liver Congress™ 2018

30/01/2018 - 13:00

CONSHOHOCKEN, Pa., Jan. 30, 2018 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL ) today announced that Week 12 Phase 2 results for MGL-3196, its first-in-class, oral, once-daily, liver-directed, [...]

Revive Therapeutics Advances Research Program of Cannabinoid-Based Therapies Targeting Liver Diseases

30/01/2018 - 13:00

TORONTO, Jan. 30, 2018 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (" Revive " or the " Company ") (TSX VENTURE:RVV) (OTCQB:RVVTF), a company focused on the research, development and commercialization of novel [...]

Dova Pharmaceuticals Announces the Appointment of Mark W. Hahn as Chief Financial Officer

30/01/2018 - 13:00

DURHAM, N.C., Jan. 30, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA ) today announced the appointment of Mark W. Hahn as the company’s Chief Financial Officer. A veteran Chief Financial Officer of [...]

VitalHub Joins Hyperledger

30/01/2018 - 13:00

TORONTO, Jan. 30, 2018 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX-V: VHI ) today announced it has joined Hyperledger ( view Hyperledger Press Release ). VitalHub joins an elite group of [...]

Transactions in relation to share buyback program

30/01/2018 - 12:31

Acting under its share buyback authorization, the GN Store Nord board of directors initiated a share buyback program on May 4, 2017 in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]

Innovate Biopharmaceuticals Announces Successful Merger Completion

30/01/2018 - 12:30

Completion of Merger with Monster Digital, Inc. Shares of combined company will begin trading on Nasdaq with new ticker INNT and will reflect a 1 for 10 reverse split on Wednesday, January 31, 2018 Concurrent financing [...]

ImmuCell Appoints Two New Members to its Board of Directors

30/01/2018 - 12:30

PORTLAND, Maine, Jan. 30, 2018 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC ) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and [...]

Resignation of Directors

30/01/2018 - 11:00

MELBOURNE, Australia, Jan. 30, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG) (Nasdaq: GENE ) (“Company”), advises that Dr Malcolm R. Brandon and Mr Grahame Leonard, AM have resigned as directors of the [...]

Helsinn Healthcare S.A.: Helsinn and the Scientific Centre of Monaco Sign Collaboration Agreement

30/01/2018 - 10:00

Helsinn and the Scientific Centre of Monaco Sign Collaboration Agreement Investigating the role of pharmacological inhibitors in kidney cancer Lugano, Switzerland, January 30, 2018 - Helsinn International Services, Sarl [...]

FIRE1 Raises EUR 40 Million in Series C Financing

30/01/2018 - 08:00

DUBLIN, Ireland, Jan. 30, 2018 (GLOBE NEWSWIRE) -- Foundry Innovation & Research 1, Ltd. (FIRE1), today announced the close of a Series C financing totaling EUR 40 Million. The financing was led by new investor [...]

Cannabis Wheaton Income Corp. Announces Expansion to Uruguay and Securing of Significant CBD-Rich Hemp Production

30/01/2018 - 07:55

VANCOUVER, British Columbia, Jan. 30, 2018 (GLOBE NEWSWIRE) -- Cannabis Wheaton Income Corp. (d/b/a Wheaton Income) (TSX-V: CBW ) (" Wheaton Income " or "Wheaton" or the " Company ") is pleased to announce that it has [...]

Innate Pharma and MedImmune enter clinical trial collaboration

30/01/2018 - 07:01

Innate Pharma and MEDIMMUnE Enter clinical trial collaboration Innate Pharma and MedImmune will evaluate the combination of Innate Pharma's first-in-class IPH5401 antibody and Imfinzi ® (durvalumab) in a Phase I/II [...]

Innate Pharma et MedImmune démarrent une collaboration clinique

30/01/2018 - 07:01

Innate Pharma et MEDIMMUNE démarrent une collaboration clinique Innate Pharma et MedImmune vont évaluer la combinaison d'IPH5401, l'anticorps « first-in-class » d'Innate Pharma, et d' Imfinzi ® (durvalumab) dans une [...]